Highlights from ASCO20 Virtual: Lung Cancer
This episode features Dr. Barbara Melosky, Dr. Parneet Cheema and Dr. Jeffrey Rothenstein. This program was made possible by unrestricted sponsorship support from AstraZeneca. Trials Discussed: Adjuvant NSCLC: CTONG 1104 a ADAURA: 00:01:11 Metastatic NSCLC: NEJ026, CONCURRENT OSIMERTINIB/GEFITINIB, JNJ-61186372, OSIMERTINIB 160MG, Poziotinib in previously treated EGFR exon 20 NSCLC patients: 00:17:21 Stage IV NSCLC, Target HER2: T-Dxd DESTINY-LUNG01, GEOMETRY, Sym015, METex14 SA and potential AR mechanisms: 00:26:25 Immunotherapy Updates in NSCLC: CHECKMATE 227 3 YEAR, CHECKMATE 9LA, CCTG BR34: 00:42:35 Extensive Stage SCLC: ECOG-ACRIN EA5161, KEYNOTE-604 a CASPIAN: 00:55:28
